Type 1 diabetes is a progressive autoimmune disease in which immune and metabolic injury severely depletes the pancreatic β-cells required for physiological insulin secretion and glucose control.
In T1D genetic susceptibility and environmental influences contribute to an autoimmune response directed against insulin-producing pancreatic β-cells. As functional β-cell capacity declines, the body progressively loses the ability to produce endogenous insulin and regulate glucose. Stage 3 disease is diagnosed when dysglycemia becomes clinically apparent and exogenous insulin is required for survival.
Insulin therapy, continuous glucose monitoring and automated delivery systems have improved care dramatically. However, even with advanced technology, people with T1D must continuously match insulin to meals, activity, illness, stress and changing physiology while managing the risks of hypoglycemia, hyperglycemia and long-term complications.
These technologies provide insulin and help manage glucose. They do not restore sufficient endogenous β-cell capacity or remove the underlying dependence on external insulin.
Insulin replacement and devices
Immune intervention
Cell replacement
Endogenous restorationA functioning β-cell does more than contain insulin. It senses glucose, processes and stores insulin correctly, and releases it dynamically as metabolic demand changes.
Elvinix aims to restore a sufficient population of protected, glucose-responsive β-cells and change both the biology and lived experience of T1D.